Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) honored board member Curtis Patton, PhD, with a joint portrait at Yale School of Medicine recognizing his decades-long contributions to medical education, mentorship, and public health.
The portrait by Mario Moore will be unveiled on December 11, 2025 at 4 p.m. at the Harvey Cushing/John Hay Whitney Medical Library. Tevogen highlighted Dr. Patton's influence on the company as it advances the ExacTcell™ T cell platform, scales Tevogen.AI predictive technologies, and pursues growth with revenue forecasts exceeding $1 billion.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TVGN gained 3.46%, reflecting a moderate positive market reaction. Argus tracked a peak move of +22.6% during that session. Argus tracked a trough of -20.4% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $90M at that time. Trading volume was very high at 4.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves, with names like KYTX up 3.21% and NTHI up 6%, while CRBU, IPHA, and VTYX declined modestly. With TVGN down 2.93% pre-news and no peers in the momentum scanner, trading looked stock-specific rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Board recognition | Positive | +3.5% | Yale portrait honor and reiterated platform, AI, and revenue ambitions. |
| Dec 08 | Growth recognition | Positive | +8.8% | NJBIZ Power List inclusion and multi‑billion‑dollar revenue outlook. |
| Nov 14 | Q3 10-Q update | Negative | -6.1% | Quarterly net loss and tight cash position despite cost controls. |
| Nov 05 | COVID trial update | Positive | -5.4% | Expanded HLA coverage and 100% viral clearance in proof‑of‑concept. |
| Nov 03 | Financial clarification | Negative | -6.4% | Clarified large accumulated deficit and need for additional capital. |
TVGN has mostly traded in line with news tone, with several negative or cautious updates followed by declines and one notably positive clinical update that saw a negative reaction.
Over the last few months, TVGN has reported clinical, financial, and recognition milestones. On Nov 3, 2025, it clarified cash vs. non‑cash losses and the need for additional capital, followed by Q3 results on Nov 14, 2025 showing continued net losses and tight liquidity. A Nov 5, 2025 COVID program update highlighted expanded HLA coverage and strong proof‑of‑concept data. Early December news emphasized growth prospects and multi‑billion‑dollar revenue outlooks. Today’s management-focused recognition at Yale fits the ongoing narrative of platform advancement and commercialization positioning.
Market Pulse Summary
This announcement highlights recognition of a long-serving board member at Yale and reiterates TVGN’s strategic focus on its ExacTcell precision T cell platform, Tevogen.AI, and revenue ambitions above $1 billion. In context with recent filings and prior news, it underscores continuity of leadership and mission rather than providing new financial or clinical data. Investors may watch future updates on funding, clinical trial initiation, and commercialization milestones to assess how this vision translates into measurable progress.
Key Terms
t cell medical
AI-generated analysis. Not financial advice.
WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board of Directors and Professor Emeritus at Yale University, as he is honored in a new joint portrait commissioned by the Yale School of Medicine’s Program for Art in Public Spaces.
The portrait celebrates the extraordinary, decades-long contributions of Dr. Patton and James Comer, MD, MPH, Maurice Falk Professor in the Child Study Center, whose work has shaped generations of medical students, residents, fellows, and early-career faculty through their unwavering commitment to mentorship, community building, and public health leadership.
Dr. Patton’s effort across academic, public and private verticals have had a lasting impact on Tevogen, particularly as the Company continues to advance its ExacTcell™ precision T cell platform, scale Tevogen.AI’s predictive technologies, and execute on its growth initiatives, all with the ultimate goal of improving patient outcomes while achieving commercial success, including revenue forecasts exceeding
The portrait, created by artist Mario Moore (MFA ’13), will be unveiled on Thursday, December 11, 2025 at 4 p.m. in the Harvey Cushing/John Hay Whitney Medical Library at Yale School of Medicine.
“Dr. Patton’s leadership and scientific vision have played a pivotal role in shaping Tevogen’s foundation,” said Dr. Ryan Saadi, Founder & CEO of Tevogen. “His legacy at Yale reinforces the strength of the Company’s mission during a period of significant momentum.”
“Dr. Patton’s brilliance is matched only by his humanity. His lifelong commitment to public health and mentorship has elevated the field and all of us fortunate enough to work with him,” commented Susan M. Podlogar, of Tevogen’s board of directors.
Tevogen Bio extends its heartfelt congratulations to Dr. Patton on this well-deserved recognition.
About Tevogen
Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/f68cfcd1-fa0f-4c28-a7a8-4299f911461d
FAQ
Who is Curtis Patton and what is his role with Tevogen (TVGN)?
When and where will the Yale portrait of Dr. Curtis Patton be unveiled?
How did Tevogen describe Dr. Patton's impact on the company (TVGN)?
Does the announcement mention Tevogen (TVGN) revenue expectations?
Who created the portrait of Dr. Patton and James Comer honored by Yale?
